Cosopt  (U.S.N.L.M.)
Dosing 1 drop bid
Chem Specs dorzolamide 2%, timolol 0.5%
Quantities 5, 10ml
Cost 103.00/10ml (generic)      Cosopt PF, 60 unit package 160.00
Class carbonic anhydrase inhibitor, beta blocker
Action Inhibition of carbonic anhydrase II slows bicarbonate formation reducing sodium and fluid transport.
Beta-receptor blockers reduce aqueous production at the non-pigmented ciliary epithelium.
Usage Indicated for the reduction of elevated IOP in patients with open-angle glaucoma
or ocular hypertension who are insufficiently responsive to beta-blockers alone.
Indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers alone.
Dorzolamide is a sulfonamide. One retrospective study1 suggested that topical
CIA's can be safely used despite a patient reported history of "sulfa alergy". Use
cautioned as sensitization may occur when sulfonamides are readministered.
Dorzolamide is a sulfonamide. One retrospective study1 suggested that topical CIA's can be safely used despite a patient reported history of "sulfa alergy". Use cautioned as sensitization may occur when sulfonamides are readministered.
Contraindications Bronchial asthma, COPD, sinus bradycardia, second or third degree atrioventricular block,
overt cardiac failure, cardiogenic shock, hypersensitivity to any component of this product.
Bronchial asthma, COPD, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock, hypersensitivity to any component of this product.
Pediatric use > 2 years
Pregnancy Category C. Teratogenicity demonstrated at 37 times the normal human ophthalmic dose.
0.0075% BAK preserved.
Preservative-free single dose units available. (Cosopt PF) Cosopt PF is not generic and
cost per 60 unit package is around $160.00.
0.0075% BAK preserved. Preservative-free single dose units available. (Cosopt PF) Cosopt PF is not generic and>, cost per 60 unit package is around $160.00.
1. Guedes GB, et al. J Ocular Pharmacol Ther. 2013;29(5):456–61.     N.L.M. DailyMed page for Cosopt         PDR page for Cosopt